Golden has been acquired by ComplyAdvantage.Read about it here ⟶

List of SBIR/STTR awards granted to MandalMed

List of SBIR/STTR awards granted to MandalMed

List of SBIR/STTR awards granted to Lumicell

List of SBIR/STTR awards granted to Alphacore, Inc.

List of SBIR/STTR awards granted to Behavioral Diagnostics

List of companies in CyberFi's investment portfolio

List of companies in Atlanta Seed Company's investment portfolio

where

SBIR/STTR Award Recipient

is

‌

MandalMed

	Name	Description	SBIR/STTR Award Recipient	Government Agency	Government Branch	Award Type	Contract Number (US Government)	Award Phase	Award Amount (USD)	Date Awarded	Official Website
	‌ MANDALMED, INC. SBIR Phase I Award, September 2018	A SBIR Phase I contract was awarded to MandalMed in September, 2018 for $299,900.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health.	‌ MandalMed		National Institutes of Health	SBIR	1R43DK107285-01A1	Phase I	299,900	September 20, 2018	sbir.gov/node/1567797
	‌ MANDALMED, INC. SBIR Phase II Award, April 2017	A SBIR Phase II contract was awarded to MandalMed in April, 2017 for $2,001,205.0 USD from the U.S. Department of Health & Human Services.	‌ MandalMed			SBIR	4R44AG054386-02	Phase II	2,001,205	April 15, 2017	sbir.gov/node/1305459
	‌ MANDALMED, INC. SBIR Phase I Award, August 2016	A SBIR Phase I contract was awarded to MandalMed in August, 2016 for $224,734.0 USD from the U.S. Department of Health & Human Services.	‌ MandalMed			SBIR	1R44AG054386-01A1	Phase I	224,734	August 15, 2016	sbir.gov/node/1198095
	‌ MANDALMED, INC. SBIR Phase I Award,	A SBIR Phase I contract was awarded to MandalMed for $250,000.0 USD from the U.S. Department of Health & Human Services.	‌ MandalMed			SBIR	1R43ES019824-01A1	Phase I	250,000		sbir.gov/node/368393
	‌ MANDALMED, INC. SBIR Phase I Award,	A SBIR Phase I contract was awarded to MandalMed for $299,958.0 USD from the U.S. Department of Health & Human Services.	‌ MandalMed			SBIR	1R43HL120645-01	Phase I	299,958		sbir.gov/content/protein-inhibitor-galectin-3-limit-fibrosis-after-myocardial-infarction-0
	‌ MANDALMED, INC. SBIR Phase I Award,	A SBIR Phase I contract was awarded to MandalMed for $255,200.0 USD from the U.S. Department of Health & Human Services.	‌ MandalMed			SBIR	1R43HD056620-01	Phase I	255,200		sbir.gov/content/human-sertoli-cell-model-study-male-reproductive-function-and-toxicity-0
	‌ MANDALMED, INC. SBIR Phase II Award,	A SBIR Phase II contract was awarded to MandalMed for $749,980.0 USD from the U.S. Department of Health & Human Services.	‌ MandalMed			SBIR	2R44HD042333-02	Phase II	749,980		sbir.gov/content/novel-ex-vivo-gene-therapy-spinal-cord-injury-0
	‌ MANDALMED, INC. SBIR Phase I Award,	A SBIR Phase I contract was awarded to MandalMed for $363,936.0 USD from the U.S. Department of Health & Human Services.	‌ MandalMed			SBIR	1R43CA135862-01A1	Phase I	363,936		sbir.gov/content/preclinical-testing-galectin-3c-multiple-myeloma-0
	‌ MANDALMED, INC. SBIR Phase I Award,	A SBIR Phase I contract was awarded to MandalMed for $155,695.0 USD from the U.S. Department of Health & Human Services.	‌ MandalMed			SBIR	1R43HD042333-01	Phase I	155,695		sbir.gov/content/novel-ex-vivo-gene-therapy-spinal-cord-injury-2
	‌ MANDALMED, INC. SBIR Phase I Award,	A SBIR Phase I contract was awarded to MandalMed for $134,000.0 USD from the U.S. Department of Health & Human Services.	‌ MandalMed			SBIR	1R43DK069128-01	Phase I	134,000		sbir.gov/content/no-donorsod-mimetics-diabetic-nephropathy-0
	‌ MANDALMED, INC. SBIR Phase I Award,	A SBIR Phase I contract was awarded to MandalMed for $236,893.0 USD from the U.S. Department of Health & Human Services.	‌ MandalMed			SBIR		Phase I	236,893		sbir.gov/content/novel-treatment-breast-cancer-truncated-galectin-3-0
	‌ MANDALMED, INC. SBIR Phase I Award,	A SBIR Phase I contract was awarded to MandalMed for $142,130.0 USD from the U.S. Department of Health & Human Services.	‌ MandalMed			SBIR		Phase I	142,130		sbir.gov/content/not-available-7889

12 results

0 selected

12 results

0 selected